No Data
No Data
CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
CervoMed Reports Plasma Biomarker Data Show Neflamapimod Lowers GFAP Levels
CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent With Neflamapimod Impacting the Underlying Disease Process in Patients With Dementia With Lewy Bodies (DLB)
Morgan Stanley Starts CervoMed at Overweight, Cites Upcoming Data
Morgan Stanley Initiates CervoMed(CRVO.US) With Buy Rating, Announces Target Price $35
Express News | Morgan Stanley Initiates Coverage On CervoMed With Overweight Rating, Announces Price Target of $35
No Data